UCB Pharma co-led a series A round for the kidney disease-focused drug developer through its UCB Ventures vehicle.
US-based kidney disease treatment developer Walden Biosciences launched on Tuesday with $51m it secured in a series A round co-led by pharmaceutical company UCB’s corporate venturing fund, UCB Ventures.
Venture capital firm Arch Venture Partners co-led the round, and Ari Nowacek, a principal at the firm, is a co-founder of Walden. Emmanuel Lacroix, vice-president and partner at UCB Pharma, is on the company’s board of directors.
Founded earlier this year, Walden is working on therapeutics designed to restore renal function…
